ArticleFrontiers in public health2025
Using surveillance data to evaluate the effectiveness of inactivated/mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the current ambit of SARS-CoV-2 XBB and JN.1 variant circulation.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the rapid evolution of the SARS-CoV-2 viruses, vaccines targeting ancestral strains remain widely used. This study evaluates the effectiveness of ancestral strains inactivated and mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the circulation of the XBB and JN.1 variants. Methods: We analyzed 2,157 severe COVID-19 cases (aged ≥50) reported to the Centre for Health Protection from the hospital authority-managed public hospitals between January 30, 2023, and January 29, 2024. Logistic regression was used to investigate the relationship between vaccination status and fatal outcomes, adjusting for age, sex, and residential status in residential care homes for the older adult (RCHE), and other demographic factors. Results: Among the 2,157 cases, 764 (35.4%) succumbed within a 28-day follow-up. Fatal outcomes were more common among older individuals, RCHE residents, and those unvaccinated or with incomplete initial vaccination (zero to two doses). Fewer deaths had received ancestral strains mRNA or inactivated booster doses compared to those not receiving booster. Univariate logistic regression revealed the lowest in-hospital mortality odds ratio for mRNA booster recipients, followed by inactivated booster recipients, and then those with completed initial vaccination (three doses). After adjusting for confounders, booster vaccination remained significantly associated with reduced in-hospital mortality. Conclusion: Vaccines based on ancestral strains maintain some degree of effectiveness against recently emerged variants, offering insights for healthcare policies in regions where earlier generations of inactivated and mRNA vaccines continue to be administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.